Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14

Tabrecta demonstrated an overall response rate of 68% and 41% in treatment-naive and previously treated METex14 patients, respectively.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: